Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Natera, Inc.

FDA 510(k) & PMA Approved Devices — 1 products

Total Devices1
Categories1
Latest FDA decision2026-05-15

SEC Filings: 1 filings on record. Latest: 10-Q (2026-08-07). View on SEC EDGAR →

TypeNumberDevice NameCodeDateActions
PMA P260004 Next generation sequencing oncology panel, somatic or germline variant detection systemPQP2026-05-15 View

Related Clinical Trials

NCT07214532Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerRECRUITINGNCT07339384Signatera Assessment in Early-Stage Endometrial CancerNOT_YET_RECRUITINGNCT07689812A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.NOT_YET_RECRUITING
↑